Cancer Research Horizons Seed Fund 

Scientist at a screen

Accelerating cutting-edge cancer treatments, diagnostics and technologies.

Our business is breakthroughs

We bring together the brightest minds, boldest ideas and best investment partners to fast-track scientific breakthroughs into patient benefit.  We invest in early-stage startup propositions and companies to bridge the gap between innovative ideas, and treatments, diagnostics and medical devices, to bring forward the day when all cancers are conquered.  

Our venture build and portfolio investments benefit from the support of our dedicated team and access to expert networks. Launched with a £15m commitment from Cancer Research UK, the Cancer Research Horizons Seed Fund builds on over 25 years of Cancer Research Horizons establishing and growing successful startup companies. We have set a target to grow the fund to £30m within 5 years.

Our investment strategy

We're an impact-driven, evergreen, venture philanthropy fund investing in promising, early-stage opportunities, worldwide, from within and beyond the Cancer Research UK network. We take a long-term view, so can take risks where others can’t. We can invest alone or alongside other like-minded investors. We don’t have to lead the round, and we'll work with local technology transfer organisations or existing investors to put the funding package together. 

Any financial returns we generate are reinvested back into the fund and into cancer research. Investment decisions are made based on the potential to leverage and attract high quality follow-on capital that will increase the chances of life-saving cancer treatments and diagnostics reaching the market.

Bowel cancer organoid. Photograph Dr Christopher Tape

Looking to fund your idea or startup?

We provide rapid-access early stage validation, Pre-Seed and Seed capital to Cancer Research UK and non-Cancer Research UK funded researchers and early-stage startup companies

People Brainstorming

Our track record

We are experienced company builders, seed investors and co-investors, with over 60 companies formed to date.

Flouro cells

Our Seed Fund team

Our fund is managed by a team with a long-standing track record of sourcing, evaluating and completing spinout and partnering deals, working alongside an independent investment committee to review applications.

Adrian Hayday

The story of GammaDelta Therapeutics

GammaDelta Therapeutics was founded on pioneering research funded in part by Cancer Research UK, led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, into gamma delta (γδ) T cells.